SCHEMBL16784368

SCHEMBL16784368

CN1C(=O)c2cccc3c(N4CCOCC4)ccc(c23)C1=O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 13/20 0.68
KMT2A Q03164 13/20 0.68
LMNA P02545 6/20 0.68
BRD1 O95696 2/20 0.64
BRPF1 P55201 2/20 0.64
TAF1 P21675 1/20 0.64
HDAC6 Q9UBN7 3/20 0.58
HDAC3 O15379 3/20 0.58
HDAC1 Q13547 3/20 0.58
HDAC8 Q9BY41 2/20 0.58
HDAC2 Q92769 2/20 0.58
HDAC11 Q96DB2 2/20 0.58
NCOR2 Q9Y618 2/20 0.58
L3MBTL1 Q9Y468 5/20 0.57
MAPK1 P28482 4/20 0.57
RAB9A P51151 2/20 0.57
HDAC10 Q969S8 1/20 0.56
MAPT P10636 4/20 0.55
HTT P42858 3/20 0.55
POLB P06746 3/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28588259 0.88 MEN1 (0.67) MEN1KMT2ALMNABRD1BRPF1
SCHEMBL7712239 0.86 MEN1 (0.72) MEN1KMT2ALMNABRD1BRPF1
SCHEMBL18648444 0.85 MEN1 (0.64) MEN1KMT2ALMNABRD1BRPF1
SCHEMBL16773474 0.85 MEN1 (0.64) MEN1KMT2ALMNABRD1BRPF1
SCHEMBL1896021 0.84 MEN1 (0.59) MEN1KMT2ALMNABRD1BRPF1
SCHEMBL11675290 0.84 MEN1 (0.59) MEN1KMT2ALMNABRD1BRPF1
SCHEMBL29564392 0.84 MEN1 (0.62) MEN1KMT2ALMNABRD1BRPF1
SCHEMBL1890453 0.84 MEN1 (0.62) MEN1KMT2ALMNABRD1BRPF1
SCHEMBL22699960 0.83 MEN1 (0.80) MEN1KMT2ALMNABRD1BRPF1
SCHEMBL28197565 0.83 HDAC6 (0.64) MEN1KMT2ALMNABRD1BRPF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220401474-A1 HDAC6-ACTIVATED MACROPHAGES, COMPOSITIONS, AND USES THEREOF MEDSTAR HEALTH 2022-12-22 US disclosed
US-9597344-B2 Sonosensitive liposome, pharmaceutical composition including the same, and method of delivering active agent to subject using the sonosensitive liposome SAMSUNG ELECTRONICS CO., LTD. (KR) 2017-03-21 US disclosed
US-9220718-B2 Sonosensitive liposome, pharmaceutical composition including the same, and method of delivering active agent to subject using the sonosensitive liposome SAMSUNG ELECTRONICS CO., LTD. (KR) 2015-12-29 US disclosed
US-20150352039-A1 SONOSENSITIVE LIPOSOME, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME, AND METHOD OF DELIVERING ACTIVE AGENT TO SUBJECT USING THE SONOSENSITIVE LIPOSOME SAMSUNG ELECTRONICS CO., LTD. (KR) 2015-12-10 US disclosed
US-20150150971-A1 SONOSENSITIVE LIPOSOME, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME, AND METHOD OF DELIVERING ACTIVE AGENT TO SUBJECT USING THE SONOSENSITIVE LIPOSOME SAMSUNG ELECTRONICS CO., LTD. (KR) 2015-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220401474-A1 HDAC6-ACTIVATED MACROPHAGES, COMPOSITIONS, AND USES THEREOF HDAC6, HDAC1, HDAC3 MEN1 4507/4885KMT2A 200/4885LMNA 3602/4885
US-20150150971-A1 SONOSENSITIVE LIPOSOME, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME, AND METHOD OF DELIVERING ACTIVE AGENT TO SUBJECT USING THE SONOSENSITIVE LIPOSOME SON, LIPA, LIPE MEN1 645/4885KMT2A 4705/4885LMNA 501/4885
US-20150352039-A1 SONOSENSITIVE LIPOSOME, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME, AND METHOD OF DELIVERING ACTIVE AGENT TO SUBJECT USING THE SONOSENSITIVE LIPOSOME SON, LIPA, LIPE MEN1 645/4885KMT2A 4705/4885LMNA 501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.